Based on our Physician & Payer Forum report entitled Physician and Payer Attitudes Towards Effient, Brilinta and Other Novel Oral Antiplatelets for ACS and CHD, Decision Resources is offering an exclusive webinar entitled Will Effient, Brilinta and Other Novel Oral Antiplatelets Gain Widespread Physician and Payer Acceptance in ACS and CHD? Because this webinar features major report findings, it is ONLY available to purchasers of this report.
Recorded live on Wednesday, August 11, 2010
This webinar, presented by Decision Resources Analyst Conor Walsh, Ph.D., answers the following questions:
- What factors drive clinician’s choice of antiplatelet strategy and what patient share does each current brand enjoy, by indication and by specialty?
- How well are current brands differentiated in each specialty and which agent performs best across a range of attributes, according to clinicians? What are clinicians’ priorities for attributes of new brands? What patient-related factors limit the use of ADP receptor antagonists such as Plavix?
- What are clinicians’ attitudes toward emerging brands and what patient share can emerging antiplatelets expect, by indication? How will the launch of new brands impact prescribing of current brands and to what extent will they be used off-label?
- How are MCOs positioning antiplatelets on their formularies and how will they position novel agents? According to pharmacy & therapeutics’ committee members and MCO pharmacy directors, what drives hospital and MCO formulary inclusion decisions?
- What are hospitals’ policies on platelet function tests and pharmacogenomic tests? What are clinicians’ attitudes toward these tests and how will policies change over the next 12 months?
Contact us to learn how you can purchase this Physician & Payer Forum report and access a recorded playback of this event.
Click here to view the invite.